top of page
19-aug_cancer-fatty-jackets.jpg.webp

Until Now...

  • The predominant approach in oncology drug discovery and development has been to oversimplify cancer cell biology by focusing on singular molecular targets.

​

  • The drugs targeting isolated pieces of cancer cell biology commonly fail in the clinic because they do not address cancer cell heterogeneity.

​

  • The rationale and design of historical combination therapies is predicated on combining anticancer drugs at their maximal tolerated doses with little emphasis on scientific rationale,

i.e. random additions of drug A and drug B.

​​

  • These historical approaches typically produce excessive toxicity and fail to advance

​the standard of care.

​

  • A paradigm shift is desperately needed to transform how we design combinatorial therapies....

The Nouveau Difference

​

  • Nouveau deploys a proprietary platform technology to accelerate the discovery and synthesis of limitless new oncology drugs.

​​

  • Our technology coupled with our pioneering expertise in nanochemistry can produce new derisked drug entities that leverage scientific rationale to generate drug candidates with superior safety, efficacy and pharmacologic features.  

​

  • The platform allows our new drug entities to be bioconjugated, enhancing honing of the therapeutic entity to the tumor and tumor microenvironment.

bottom of page